Leap Therapeutics, Inc. entered into an Asset Purchase Agreement with Flame Biosciences LLC and AlmataBio, Inc., resulting in the sale of assets related to IL-1 antibodies for $500,000 in cash and contingent milestone payments of up to $70 million.